New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
09:09 EDTEGRXEagle Pharmaceuticals' licensor granted U.S. patent for dantrolene
Eagle Pharmaceuticals announced that the United States Patent and Trademark Office has granted Patent No. 8,685,460 for the treatment of heat stroke with Eagle’s dantrolene sodium for injectable suspension. This patent issued expires in 2023. Eagle’s dantrolene formulation for the treatment of Exertional Heat Stroke was granted Orphan Drug designation by the Food and Drug Administration on September 25, 2012. Eagle is currently developing dantrolene in this new EHS indication. The company filed an NDA in January 2014 for Ryanodex in the treatment of Malignant Hyperthermia which was granted a priority review and has a PDUFA date of July 22, 2014. Ryanodex for the treatment of MH has also received Orphan Drug designation.
News For EGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
10:26 EDTEGRXEagle Pharmaceuticals granted seven years of market exclusivity to Ryanodex
Subscribe for More Information
February 18, 2015
07:45 EDTEGRXEagle Pharmaceuticals price target raised to $37 from $30 at Cantor
Subscribe for More Information
07:13 EDTEGRXEagle Pharmaceuticals target raised to $43 from $25 at William Blair
William Blair raised its price target for Eagle Pharmaceuticals (EGRX) to $43 saying the company's agreement with Teva (TEVA) removes a major overhang on the stock. William Blair says the deal is a significant positive for Eagle since it removes litigation risk and moves the company immediately into profitability. It keeps an Outperform rating on the stock.
February 17, 2015
16:07 EDTEGRXEagle Pharmaceuticals reports Q4 EPS (39c), consensus (49c)
Subscribe for More Information
08:39 EDTEGRXTeva deal small but important, says BMO Capital
Subscribe for More Information
07:04 EDTEGRXTeva, Eagle enter license agreement for EP-3102
Teva Pharmaceutical Industries (TEVA) and Eagle Pharmaceuticals (EGRX) announce that the companies have entered into an exclusive license agreement for EP-3102, Eagle’s bendamustine hydrochloride rapid infusion product for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva will be responsible for all U.S. commercial activities for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting post-approval clinical studies, if required, and initially supplying drug product to Teva. As part of the agreement, Teva will waive its orphan drug exclusivities for NHL and CLL with respect to EP-3102, which should allow the product to come to market more quickly. Under the terms of the exclusive license agreement, Eagle will receive an upfront cash payment of $30M and is eligible to receive up to $90M in additional milestone payments. In addition, Eagle will receive double-digit royalties on net sales of the product, assuming FDA approval. The companies will also settle the pending patent infringement action between them.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use